Validation of a multi-ancestry polygenic risk score and age-specific risks of prostate cancer: A meta-analysis within diverse populations

Fei Chen, Burcu F. Darst, Ravi Madduri, Alex A Rodriguez, Xin Sheng, Christopher T. Rentsch, Caroline Andrews, Wei Tang, Adam S. Kibel, Anna Plym, Kelly Cho, Mohamed Jalloh, Sérigne Maguèye Gueye, Lamine Niang, Olufemi J. Ogunbiyi, Olufemi Popoola, Akindele O. Adebiyi, Oseremen I. Aisuodionoe-Shadrach, Hafees O. Ajibola, Mustapha A. Jamda, Olabode P. Oluwole, Maxwell M. Nwegbu, Ben Adusei, Sunny Mante, Afua O.d. Abrahams, James E. Mensah, Andrew A. Adjei, Halimatou Diop‐Ndiaye, Joseph Lachance, Timothy R. Rebbeck, Stefan Ambs, J. Michael Gaziano, Amy C. Justice, David V. Conti, Christopher A. HaimaneLife 2022 · DOI

TL;DR

This study validates a multi-ancestry polygenic risk score (PRS) for prostate cancer, demonstrating its effectiveness in stratifying risk across European, African, and Hispanic populations. The PRS shows a significant association with prostate cancer risk, with its predictive power diminishing with increasing age, suggesting a need for age-specific risk assessment in screening strategies.

What Problem Does This Paper Address?

Prostate cancer is a significant health concern, particularly for African ancestry men who experience higher incidence rates. While genetic factors play a crucial role in susceptibility, existing polygenic risk scores (PRS) have often been developed and validated primarily in European ancestry populations, potentially limiting their utility in diverse groups. Furthermore, the interplay between genetic risk and age in prostate cancer development is not fully understood, complicating risk stratification and screening recommendations. This paper addresses the need for a validated, multi-ancestry PRS that can accurately assess prostate cancer risk across different populations and considers the influence of age on this risk.

Methods

The researchers employed a meta-analysis approach to validate a previously developed multi-ancestry polygenic risk score (PRS) for prostate cancer. This PRS is based on 269 common genetic variants identified through a trans-ancestry genome-wide association study. The validation involved combining results from several independent replication studies across European, African, and Hispanic populations. For each ancestry group, the association between PRS and prostate cancer risk was evaluated separately and then pooled using a fixed-effects inverse-variance-weighted meta-analysis. To assess age-specific effects, age-stratified analyses were conducted in two large replication studies (UK Biobank and Million Veteran Program). Absolute risks of prostate cancer were then calculated for different PRS categories and age groups.

Datasets

The study utilized data from several large-scale datasets for validation and meta-analysis:

  • Million Veteran Program (MVP): A large dataset of US veterans, including European, African, and Hispanic ancestry participants.
  • UK Biobank: A large UK-based prospective cohort study with European ancestry participants.
  • Mass General Brigham (MGB) Biobank: A dataset with European and African ancestry participants.
  • California and Uganda Prostate Cancer Study (CA UG): A study focusing on African ancestry populations.
  • Men of African Descent and Carcinoma of the Prostate (MADCaP) Network: A study on African ancestry populations.
  • Maryland Prostate Cancer Case-Control Study (NCI-MD): A study on African ancestry populations.

These datasets were used to replicate the PRS's performance and to conduct age-stratified analyses.

Key Insights and Ideas

  • PRS is a robust risk stratifier across ancestries: The study provides strong evidence that the multi-ancestry PRS effectively stratifies prostate cancer risk not only in European but also in African and Hispanic populations, addressing a critical gap in current PRS utility.
  • Age significantly modifies PRS performance: The PRS shows a stronger association with prostate cancer risk in younger men, with its predictive power diminishing as men age. This highlights the importance of considering age alongside genetic risk for more accurate risk assessment.
  • Potential for improved screening strategies: The age-specific risk estimates derived from the PRS could inform personalized screening guidelines, potentially reducing overdiagnosis in lower-risk individuals and ensuring timely detection in higher-risk men.
  • Need for continued research in underrepresented populations: While the PRS performs well across ancestries, the study notes consistently lower performance in African ancestry men, underscoring the ongoing need for larger GWAS and fine-mapping efforts in these populations to further improve PRS accuracy.

Key Results

  • The multi-ancestry PRS was strongly associated with prostate cancer risk across all three major populations studied.
  • In European ancestry men, the odds ratio (OR) for the top PRS decile (90-100%) compared to the average (40-60%) was 3.8-fold. For African ancestry men, the OR was 2.8-fold, and for Hispanic men, it was 3.2-fold.
  • The PRS showed a significant age-related effect modification. For European ancestry men in the top PRS decile, the OR was 7.11 for men ≤55 years, decreasing to 2.79 for men >70 years.
  • Men in the top PRS decile reached a 5% absolute prostate cancer risk approximately 10 years younger than men in the average PRS category.
  • The PRS did not consistently differentiate aggressive from nonaggressive prostate cancer, although some trends were observed in specific populations.

Limitations and Future Work

The authors acknowledge that the PRS performance was consistently lower in African ancestry men compared to European ancestry men, reinforcing the need for expanded GWAS and fine-mapping efforts in African populations. While the study demonstrates the PRS's effectiveness in risk stratification, they suggest that a clinical study is warranted to determine its utility in risk-stratified screening and early detection. The study also notes that the PRS did not consistently differentiate aggressive from nonaggressive prostate cancer, which could be a focus for future research. The authors also highlight the potential for PRS-stratified screening to reduce overdiagnosis, particularly in men with lower genetic risk, and call for further studies to evaluate the clinical utility of this multi-ancestry PRS in diverse populations for shared decision-making in prostate cancer screening.

Summary updated

Abstract

This work was supported by the National Cancer Institute at the National Institutes of Health (grant numbers U19 CA214253 to C.A.H., U01 CA257328 to C.A.H., U19 CA148537 to C.A.H., R01 CA165862 to C.A.H., K99 CA246063 to B.F.D, and T32CA229110 to F.C), the Prostate Cancer Foundation (grants 21YOUN11 to B.F.D. and 20CHAS03 to C.A.H.), the Achievement Rewards for College Scientists Foundation Los Angeles Founder Chapter to B.F.D, and the Million Veteran Program-MVP017. This research has been conducted using the UK Biobank Resource under application number 42195. This research is based on data from the Million Veteran Program, Office of Research and Development, and the Veterans Health Administration. This publication does not represent the views of the Department of Veteran Affairs or the United States Government.
BibTeX
@inproceedings{chen2022validation,
  author = {Fei Chen and Burcu F. Darst and Ravi Madduri and Alex A Rodriguez and Xin Sheng and Christopher T. Rentsch and Caroline Andrews and Wei Tang and Adam S. Kibel and Anna Plym and Kelly Cho and Mohamed Jalloh and Sérigne Maguèye Gueye and Lamine Niang and Olufemi J. Ogunbiyi and Olufemi Popoola and Akindele O. Adebiyi and Oseremen I. Aisuodionoe-Shadrach and Hafees O. Ajibola and Mustapha A. Jamda and Olabode P. Oluwole and Maxwell M. Nwegbu and Ben Adusei and Sunny Mante and Afua O.D. Abrahams and James E. Mensah and Andrew A. Adjei and Halimatou Diop‐Ndiaye and Joseph Lachance and Timothy R. Rebbeck and Stefan Ambs and J. Michael Gaziano and Amy C. Justice and David V. Conti and Christopher A. Haiman},
  title = {{Validation of a multi-ancestry polygenic risk score and age-specific risks of prostate cancer: A meta-analysis within diverse populations}},
  booktitle = {eLife},
  year = {2022},
  doi = {10.7554/elife.78304},
}
Figure